TuisAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Vorige sluiting
$38,20
Dagwisseling
$37,75 - $39,69
Jaarwisseling
$23,42 - $62,58
Markkapitalisasie
2,25 mjd USD
Gemiddelde volume
880,78 k
P/V-verhouding
3,51
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 12,46 m | 44,57% |
Bedryfskoste | 45,87 m | 29,08% |
Netto inkomste | -112,02 m | -16,54% |
Netto winsgrens | -899,40 | 19,39% |
Wins per aandeel | -1,93 | -14,20% |
EBITDA | -125,80 m | -20,70% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 938,94 m | 64,76% |
Totale bates | 1,47 mjd | 90,31% |
Totale aanspreeklikheid | 101,68 m | -9,66% |
Totale ekwiteit | 1,37 mjd | — |
Uitstaande aandele | 58,10 m | — |
Prys om te bespreek | 1,62 | — |
Opbrengs op bates | -20,99% | — |
Opbrengs op kapitaal | -21,62% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -112,02 m | -16,54% |
Kontant van bedrywe | -77,12 m | -6,25% |
Kontant van beleggings | 78,97 m | 112,02% |
Kontant van finansiering | 65,00 k | -94,09% |
Netto kontantverandering | 1,91 m | 105,57% |
Beskikbare kontantvloei | -51,97 m | -32,43% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
487
